Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 529 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab June 5, 2025 TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma April 17, 2018 Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL September 21, 2021 Load more HOT NEWS Re-Thinking Community David Dangoor: “Education is a treasure that you give someone and... Visits to Online Breast Cancer Communities Could Help Policy Makers and... Percentage of Cancer Patients Who Are Eligible for and Respond to...
